119 related articles for article (PubMed ID: 25414433)
1. The end of knight-errantry in GVHD studies.
de Lima M
Blood; 2014 Nov; 124(22):3178-9. PubMed ID: 25414433
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
Bolaños-Meade J; Logan BR; Alousi AM; Antin JH; Barowski K; Carter SL; Goldstein SC; Hexner EO; Horowitz MM; Lee SJ; Levine JE; MacMillan ML; Martin PJ; Mendizabal AM; Nakamura R; Pasquini MC; Weisdorf DJ; Westervelt P; Ho VT
Blood; 2014 Nov; 124(22):3221-7; quiz 3335. PubMed ID: 25170121
[TBL] [Abstract][Full Text] [Related]
3. Unusual presentation of graft-versus-host disease in pediatric liver transplant recipients: evidence of late and recurrent disease.
Pinna AD; Weppler D; Berho M; Masetti M; DeFaria W; Kato T; Thompson J; Ricordi C; Tzakis AG
Pediatr Transplant; 1999 Aug; 3(3):236-42. PubMed ID: 10487286
[TBL] [Abstract][Full Text] [Related]
4. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
[TBL] [Abstract][Full Text] [Related]
6. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease.
Leiter U; Kaskel P; Krähn G; Gottlöber P; Bunjes D; Peter RU; Kerscher M
Photodermatol Photoimmunol Photomed; 2002 Aug; 18(4):183-90. PubMed ID: 12390673
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.
Mookerjee B; Altomonte V; Vogelsang G
Bone Marrow Transplant; 1999 Sep; 24(5):517-20. PubMed ID: 10482936
[TBL] [Abstract][Full Text] [Related]
8. Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis.
Okamura A; Shimoyama M; Ishii S; Wakahashi K; Asada N; Kawano H; Kawamori Y; Nishikawa S; Minagawa K; Katayama Y; Matsui T
Bone Marrow Transplant; 2011 Jan; 46(1):148-9. PubMed ID: 20228852
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.
Basara N; Blau WI; Kiehl MG; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306
[No Abstract] [Full Text] [Related]
10. Administration of mycophenolate mofetil in a murine model of acute graft-versus-host disease after bone marrow transplantation.
van Leeuwen L; Guiffre AK; Sewell WA; Vos BJ; Rainer S; Atkinson K
Transplantation; 1997 Oct; 64(8):1097-101. PubMed ID: 9355822
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
[TBL] [Abstract][Full Text] [Related]
12. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy.
Grundmann-Kollmann M; Behrens S; Gruss C; Gottlöber P; Peter RU; Kerscher M
J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):134-6. PubMed ID: 10607334
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients.
Baudard M; Vincent A; Moreau P; Kergueris MF; Harousseau JL; Milpied N
Bone Marrow Transplant; 2002 Sep; 30(5):287-95. PubMed ID: 12209350
[TBL] [Abstract][Full Text] [Related]
14. [Mycophenolate mofetil in renal transplantation].
Uchida K
Nihon Rinsho; 2005 May; 63 Suppl 5():684-91. PubMed ID: 15954430
[No Abstract] [Full Text] [Related]
15. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
16. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
Takami A; Mochizuki K; Okumura H; Ito S; Suga Y; Yamazaki H; Yamazaki M; Kondo Y; Asakura H; Nakao S
Int J Hematol; 2006 Jan; 83(1):80-5. PubMed ID: 16443558
[TBL] [Abstract][Full Text] [Related]
18. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Rodriguez V; Anderson PM; Trotz BA; Arndt CA; Allen JA; Khan SP
Pediatr Blood Cancer; 2007 Aug; 49(2):212-5. PubMed ID: 16261610
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
